Surgical Outcome and Predictors of Overall Survival of Stage I-III Appendiceal Adenocarcinoma

Surgical Outcome and Predictors of Overall Survival of Stage I-III Appendiceal Adenocarcinoma; a National Cancer Database Analysis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05452382

Enrollment

2607

Registered

2022-07-11

Start date

2005-01-01

Completion date

2022-07-06

Last updated

2022-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Appendiceal Cancer

Brief summary

A few studies investigated the predictors of overall survival in appendiceal adenocarcinoma. A SEER database analysis of 1404 patients with appendiceal adenocarcinoma found that older age, T4 tumors, N1-2 stage, poorly differentiated carcinoma, and distant metastasis were significantly predictive of poorer survival. Another small single-center study including 49 appendiceal cancer patients reported female gender and low-grade adenocarcinoma to be associated with increased overall survival. However, these previous analyses did not take into account some important prognosticators of survival such as patients' comorbidities and functional status, pathologic parameters such as lymphovascular invasion, and adjuvant systemic treatment. Therefore, we used the National Cancer Database (NCDB) to conduct a comprehensive analysis of the predictors of overall survival after surgical treatment of stage I-III appendiceal adenocarcinoma.

Interventions

PROCEDUREPartial colecctomy

Segmental resection of appendiceal adenocarcinoma including terminal ileum and cecum

PROCEDUREHemicolectomy

Formal right hemicolectomy including terminal ileum, cecum, and ascending colon

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* patients with non-metastatic appendiceal adenocarcinoma who underwent surgical resection

Exclusion criteria

* Patients with other pathologic types of appendiceal cancer * Patients with clinical stage IV or unknown stage * Patients who did not undergo surgery, underwent local excision, or had unknown/non-specified surgery

Design outcomes

Primary

Measure	Time frame	Description
Overall survival	60 months	Percent of patients who were alive at five years of follow-up

Secondary

Measure	Time frame	Description
Positive resection margins	Immediate postoperative	the rate of surgical margins infiltrated by malignancy

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026